Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoach, Paul J-
dc.contributor.authorFrancis, Roslyn-
dc.contributor.authorEmmett, Louise-
dc.contributor.authorHsiao, Edward-
dc.contributor.authorKneebone, Andrew-
dc.contributor.authorHruby, George-
dc.contributor.authorEade, Thomas-
dc.contributor.authorNguyen, Quoc A-
dc.contributor.authorThompson, Benjamin D-
dc.contributor.authorCusick, Thomas-
dc.contributor.authorMcCarthy, Michael-
dc.contributor.authorTang, Colin-
dc.contributor.authorHo, Bao-
dc.contributor.authorStricker, Philip D-
dc.contributor.authorScott, Andrew M-
dc.identifier.citationJournal of nuclear medicine : official publication, Society of Nuclear Medicine 2018; 59(1): 82-88-
dc.description.abstract68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate follow-up questionnaire was completed after the 68Ga-PSMA PET/CT scan results were available to determine whether the management plan would change. Results: A total of 431 patients with prostate cancer from 4 Australian centers had pre- and post-68Ga-PSMA management plans completed. Scans were obtained for primary staging of intermediate- and high-risk disease in 25% of patients and for restaging/biochemical recurrence in 75% of patients. Overall, 68Ga-PSMA PET/CT scanning led to a change in planned management in 51% of patients. The impact was greater in the group of patients with biochemical failure after definitive surgery or radiation treatment (62% change in management intent) than in patients undergoing primary staging (21% change). Imaging with 68Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27% of patients, locoregional lymph nodes in 39%, and distant metastatic disease in 16%. Conclusion:68Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. These results demonstrate the potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer.-
dc.subjectmanagement impact-
dc.subjectprostate cancer-
dc.titleThe Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study.-
dc.typeJournal Article-
dc.typeMulticenter Study-
dc.typeResearch Support, Non-U.S. Gov't-
dc.identifier.journaltitleJournal of nuclear medicine : official publication, Society of Nuclear Medicine-
dc.identifier.affiliationSir Charles Gairdner Hospital, Perth, Australiaen
dc.identifier.affiliationUniversity of Western Australia, Perth, Australiaen
dc.identifier.affiliationRoyal North Shore Hospital, Sydney, Australiaen
dc.identifier.affiliationThe Garvan Institute of Medical Research, Sydney, Australiaen
dc.identifier.affiliationSt Vincent's Hospital, Sydney, Australiaen
dc.identifier.affiliationAustralasian Radiopharmaceutical Trials Network, Sydney, Australiaen
dc.identifier.affiliationUniversity of New South Wales, Sydney, Australiaen
dc.identifier.affiliationAustralian Prostate Cancer Research Centre-New South Wales (APCRC-NSW), Sydney, Australiaen
dc.identifier.affiliationFiona Stanley Hospital, Perth, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationUniversity of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationRoyal North Shore Hospital, Sydney, Australiaen
dc.identifier.affiliationSt Vincent's Prostate Cancer Centre, Sydney, Australiaen
dc.identifier.affiliationUniversity of Sydney, Sydney, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Australiaen
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.